Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Efficient Derivation of Functional Floor Plate Tissue from Human Embryonic Stem Cells
Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J., & Studer, L. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.001 · Cited by 209 · cited 1×
“The dual SMAD inhibition protocol has been employed to generate floor plate tissue from human ESC”
MethodRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“A potential solution is to utilize reprogamming technology to generate disease-specific induced pluripotent stem cells (iPSCs”
BackgroundAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“Results were normalized to human TBP using the comparative C(T) metho”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Directed differentiation to dopaminergic neurons We used a feeder-free monolayer culture method of inducing neural differentiation under defined conditions, via dual inhibition of SMAD signallin”
Method
Cited by
Items 401–484 of 484
Martí, Y., Nürnberg, E., Horschitz, S., Hafner, M., Schloss, P. D., Meyer‐Lindenberg, A., & Lau, T. (2017) · Journal of Cellular Biotechnology · doi:10.3233/jcb-179007 · Cited by 1
“Generation of hiPS cells from adult human skin fibroblasts by sendaiviral reprogramming: (A) Exemplary images showing morphological differences between healthy donor human skin fibroblasts, healthy donor-derived hiPS cells (hiPSCcontrol), and patient donor-derived hiPS cells (hiPSCPD), the latter established by Divine…”
BackgroundInfluentialKumari, A., Chaudhary, A., & Haque, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-8562-0_5 · Cited by 1
Engineering Gene and Protein Switches for Regulation of Lineage‐Specifying Transcription Factors
Teixeira, A. P., Franko, N., & Fussenegger, M. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28920 · Cited by 1
“(d) NAS2 cell line (Devine et al. 2011).”
Begh, M. Z. A., Zehravi, M., Bhuiyan, M. A. K., Molla, M. R., Raman, K., Emran, T. B., Ullah, H., Ahmad, I. S., Osman, H., & Khandaker, M. U. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156013 · Cited by 1
Cambiando la identidad celular para crear una verdadera medicina personalizada
Mostajo-Radji, M. A., & Ferreira, L. (2012) · Dialnet (Universidad de la Rioja) · Cited by 2
Pluripotent Stem Cell-Derived Dopaminergic Neurons As Models of Neurodegeneration
Watmuff, B., Hartley, B. J., Hunt, C. P. J., Pouton, C. W., & Haynes, J. M. (2013) · Future Neurology · doi:10.2217/fnl.13.50 · Cited by 1
Arán, B., Raya, Á., & Veiga, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90695-9_14 · Cited by 1
Therapeutic Applications of Induced Pluripotent Stem Cell Use in Parkinson’s Disease Models
Baniadam, K., Tranchina, S., Lawlor, M.-K., & Kakazu, J. (2021) · Georgetown Medical Review · doi:10.52504/001c.29784 · Cited by 1
Creating a protein-protein interaction network for alpha-synuclein
Könn, M. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7491 · Cited by 2
Advances in Induced Pluripotent Stem Cell Technologies
Pal, R., Rao, M. S., Vemuri, M. C., Verma, P. J., & Dinnyés, A. (2012) · Stem Cells International · doi:10.1155/2012/850201 · Cited by 1
Shah, M. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-17133 · Cited by 1
Jarazo, J. (2014) · Louisiana State University · doi:10.31390/gradschool_theses.2646 · Cited by 1
“Patient specific iPSCs were used to recreate the behavior of cells caused by different diseases such as Parkinson’s, Alzheimer’s and schizophrenia (Brennand et al., 2011; Devine et al., 2011; Israel et al., 2012; Yamanaka, 2012).”
MethodA de novo human MYCBP2 variant enhances memory persistence across speciesPreprint
Papassotiropoulos, A., Nesterenko, D., Beck, D., Böck, D., Petrovska, J., Arnold, A. W., LePort, A. K. R., Freytag, V., Schicktanz, N., Coynel, D., et al. (2024) · medRxiv · doi:10.1101/2024.12.18.24319147 · Cited by 1
Regulation of NFATc3 stability by SUMO and E3 ubiquitin-ligases Trim39 and Trim17
Basu-Shrivastava, M. (2020) · theses.fr (ABES) · doi:10.70675/0aa33054zc607z413dz8aedz05ed052d5438 · Cited by 1
Clinical application progress of induced pluripotent stem cells (iPSCs)
HUANG, C., Jiang, S., & Peng, J. (2014) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/972013-894
Tafaleng, E. N. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Disease Modeling and Drug Discovery Using Human Pluripotent Stem Cells
Honoré, C., & Hansson, M. D. (2013) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4614-8066-2_15
RCSN Cell System for Identifying Dopaminergic Neurotoxicity
Fernández, P. C., Codelia, R. C., & Segura‐Aguilar, J. (2013)
Humane Stammzellen: eine Perspektive für den Morbus Parkinson?
Schlachetzki, J. C. M., & Winkler, J. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0892-4
“2: Zelluläre und biochemische Phänotypen aus induzierten pluripotenten Stammzellen (IPSZ) gewonnenen Nervenzellen bei Parkinson-Syndromen Gen Mutationen Phänotyp α-Synuklein (SNCA) [11] — Triplikation — α-Synuklein erhöht Parkin [12, 13] — Heterozygote/Homozygote Deletionen von Exon 3 und 5/ Homozygote Deletion von Ex…”
Pluripotent Stem Cells and Human Diseases*
Zhang, W., & Liu, G. (2011) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2011.00466
Pluripotent stem cell-derived endothelial cells for vascular regeneration
Skinner, E. M. (2015) · ERA
Induced Pluripotent Stem Cell, a Rising Star in Regenerative Medicine
Mao, Y., Wang, Y., Wang, L., & Zhou, Q. (2015) · Translational medicine research · doi:10.1007/978-94-017-7273-0_4
Progress and Prospects: Induced Pluripotent Stem Cell Research for Neurological Diseases
Ito, D., & Suzuki, N. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.3230
Induced Pluripotent Stem Cells (iPSCs) to Study and Treat Movement Disorders
Datta, D., & Kim, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00009-3
Dillen, Y. (2015) · Document Server@UHasselt (UHasselt)
Lehtonen, Š., Lehtonen, M., & Koıstınaho, J. (2016) · InTech eBooks · doi:10.5772/62851
Stem cells in Parkinson’s disease: an updatePreprint
Gollamudi, S. (2016) · doi:10.15200/winn.148233.37308
The stem cell cocktail: neural reprogramming just got easier
Bengoa‐Vergniory, N., & Kypta, R. M. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.09.11
Personalized Medicine of Central Nervous System Diseases and Disorders: Looking Toward the Future
Mladinić, M., & Anzić, S. A. (2016) · Europeanization and globalization · doi:10.1007/978-3-319-39349-0_12
Degeneration mechanisms in human dopaminergic neurons
Pöltl, D. (2012) · KOPS (University of Konstanz)
5 Stem Cells for Parkinson’s Disease
Lamba, D. A. (2017) · CRC Press eBooks · doi:10.1201/9781315402185-6
Alpha-synuclein expression influences the processing of the amyloid precursor protein
Hall‐Roberts, H. (2016) · The University of Bath Online Publications Store (The University of Bath)
Eren, E., Erkan, E. P., Genç, Ş., & Genc, K. K. (2017) · Stem cells in clinical applications · doi:10.1007/978-3-319-59165-0_2
Generation of knockout human iPSCs to investigate genes associated with telomere length
Shamkhi, N. (2017) · Figshare
Li, S. (2020) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/740/1/012128
Highly enriched hiPSC-derived midbrain dopaminergic neurons robustly models Parkinson’s diseasePreprint
Virdi, G. S., Choi, M. L., Yao, Z., Evans, J. R., Athauda, D. S., Melandri, D., Sylantyev, S., Abramov, A. Y., Patani, R., & Gandhi, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.08.287797
A new area of stem cell therapy for Parkinson disease
Hassan, K. M., Alqarni, Z. H., Almontashri, A. A., Allubly, A. M., Alalmaee, K. A., Alhalawani, F. A., Alshalfan, F. M., Anbarserri, M. M., Almalki, M. S., Tai, M. A., et al. (2020) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20204402
“These sources of changes have also been seen in other iPSC models.(11) That is to said, generating several independent iPSC lines from each patient involved in a study of this nature is a must and this is to examine the efficiency of neutralization for fair comparisons to be made.”
BackgroundRecapitulating Parkinson’s disease pathology in a three-dimensional neural cell culture model
Taylor-Whiteley, T. R. (2019) · Sheffield Hallam University · doi:10.7190/shu-thesis-00321 · Cited by 1
Ma, L., Wu, Q., Schmidt, M., & Morrow, E. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.20.445025
“…Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, schizophrenia, and autism (Brennand et al., 2011; Chae et al., 2012; Chen et al., 2020; Devine et al., 2011; Mungenast et al., 2016; Nehme and Barrett, 2020; Sullivan and Young-Pearse, 2017; Takahashi and Yamanaka, 2006; Tcw, 2019;…”
Induced pluripotent stem cells in intestinal diseases
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Okaruefe, C. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821269-1.00003-5
RCSN Cell System for Identifying Dopaminergic Neurotoxicity
Caviedes, P. A., Caviedes, R., & Segura‐Aguilar, J. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_56
RCSN Cell System for Identifying Dopaminergic Neurotoxicity
Caviedes, P. A., Caviedes, R., & Segura‐Aguilar, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_56-1
A Preview of Selected Articles
Atkinson, S. P. (2020) · Stem Cells · doi:10.1002/stem.3195
(2014) · Elsevier eBooks · doi:10.1016/b978-1-907568-42-8.50016-2
MODELS OF PARKINSON'S DISEASE IN THE LABORATORY ANIMALS
Bogorodova, V. I., Borozdenko, D. A., Kiseleva, N. M., & Vad.V., N. (2022) · Bulletin Biomedicine and sociology · doi:10.26787/nydha-2618-8783-2022-7-1-47-65
Varderidou, S. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1458
Improving three-dimensional human pluripotent cell culture efficiency via surface molecule coating
Li, Q., Pan, Y., Han, L., Yang, Y., Wu, X., & Lei, Y. (2022) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2022.1031395 · Cited by 1
“hPSC-derived cells have been widely used to model genetic and environmental diseases (Brennand et al., 2011; Devine et al., 2011; Israel et al., 2012; Ambasudhan et al., 2013; Kondo et al., 2013; Reinhardt et al., 2013; Woodruff et al., 2013; Young et al., 2015; Soldner et al., 2016).”
MethodModels of Neurodegenerative Diseases
Maharjan, N., & Saxena, S. (2022) · Learning materials in biosciences · doi:10.1007/978-3-031-07793-7_10 · Cited by 1
Induced Pluripotent Stem Cells: Progress toward Clinical Translation from Bench to Bedside
Fakoya, A. O. J., Omole, A. E., Satyadev, N., & Haider, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-19-2655-6_40
RCSN Cell System for Identifying Dopaminergic Neurotoxicity
Caviedes, P. A., Caviedes, R., & Segura‐Aguilar, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_56
Iwasaki, M., Drummond, N. J., McNay, D. E. G., Canham, M. A., Tikhomirov, D., Arafa, D., Lelos, M. J., Morizane, A., & Kunath, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2996413/v1
Self-citationRegenerative Medicine and Stem Cell Treatment
Kaur, J., Kalia, N., Malik, S., Kumar, R., Desai, M., Sharma, A., & Grewal, G. K. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-4439-2.ch009
Roles of Ipsc in Advancing Treatments for Neurological DisordersPreprint
Zhang, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4818803
Castonguay, A.-M., Morin, B., Parent, M., Durcan, T. M., Luo, W., Shlaifer, I., Julien, J., Gravel, C., & Lévesque, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.09.612044
The OMICS and PD models: Hopes or hypes
Elsamman, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16128-5.00020-7
Hasenpusch‐Theil, K., Lesayová, A., Kozić, Z., Beltrán, M., Wilson, G., Henderson, N. C., Dando, O., & Theil, T. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03615-2 · Cited by 1
RatDISCO, a tissue clearing and immunolabelling protocol for large rat brainsPreprint
Craigie, K. J., Till, S. M., van de Gevel, B., Vandrey, B., Strangward, P., Sieger, D., Gonzalez‐Sulser, A., Kind, P., Rochefort, N. L., Duguid, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.17.670723
Blumenthal, Y., Imamura, K., & Inoue, H. (2025) · Current human cell research and applications · doi:10.1007/978-981-95-0587-6_10
Genome Editing and Human-Induced Pluripotent Stem Cells Facilitate Parkinson’s Disease Modeling
Polanco, C. M., Inzunza, J., Nalvarte, I., & Arias, J. (2025) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-94101-6_3
Kolotyeva, N. A., С., М. Р., Rozanova, N. A., Berdnikov, A. K., Novikova, S. V., & Komleva, Y. K. (2025) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1386 · Cited by 1
Ullah, A., Rehman, U. U., Zeb, Y., Ahmad, R., & Aljohani, F. S. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2593161
Stem Cell Therapy for Neurological Disorders: From Bench to Bedside
Barbuti, P. A. (2014) · Springer eBooks · doi:10.1007/978-81-322-2110-4_4
Lv, Y., Qin, Y., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22662365
Suzuki, H., Egawa, N., Imamura, K., Kondo, T., Enami, T., Tsukita, K., Suga, M., Yada, Y., Shibukawa, R., Takahashi, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25347265
Lin, M., Mackie, P. M., Shaerzadeh, F., Gamble‐George, J., Miller, D. R., Martyniuk, C. J., & Khoshbouei, H. (2021) · Figshare · doi:10.6084/m9.figshare.14746392
Lv, Y., Qin, Y., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22662362
Lin, M., Mackie, P. M., Shaerzadeh, F., Gamble‐George, J., Miller, D. R., Martyniuk, C. J., & Khoshbouei, H. (2021) · Figshare · doi:10.6084/m9.figshare.14746395
Lv, Y., Qin, Y., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22662368
Suzuki, H., Egawa, N., Imamura, K., Kondo, T., Enami, T., Tsukita, K., Suga, M., Yada, Y., Shibukawa, R., Takahashi, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26689388
Suzuki, H., Egawa, N., Imamura, K., Kondo, T., Enami, T., Tsukita, K., Suga, M., Yada, Y., Shibukawa, R., Takahashi, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26689391
Lv, Y., Qin, Y., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22662371
Suzuki, H., Egawa, N., Imamura, K., Kondo, T., Enami, T., Tsukita, K., Suga, M., Yada, Y., Shibukawa, R., Takahashi, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25347181
Lv, Y., Qin, Y., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22662359
Lin, M., Mackie, P. M., Shaerzadeh, F., Gamble‐George, J., Miller, D. R., Martyniuk, C. J., & Khoshbouei, H. (2021) · Figshare · doi:10.6084/m9.figshare.14746398
From mice to clinical relevance: humanizing neuroscience with human-based model systems
Bak, A., van Loo, K. M. J., Kronenberg‐Versteeg, D., & Koch, H. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1776439
“Protocols for deriving midbrain dopaminergic neurons from iPSCs reliably capture disease-relevant hallmarks such as alpha-synuclein aggregation, mitochondrial dysfunction, and oxidative stress (Devine et al., 2011; Kriks et al., 2011).”
O’Connor, C., Mullally, R. E., Chávez, J. C. P., Dobricic, M., McCoy, E., Maughan, J., Stewart, R., Saha, C., O'Sullivan, J., McCarthy, H. O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.22.719922
“Human iPSC line s (NAS2 line: donated by Dr Tilo Kunath’s laboratory [84]; CS29Ials-C9n1.ISOD7 line: obtained from Cedars Sinai Bio-manufacturing Centre, California, USA) were differentiated into cortical neurons using a modified version of the dual-SMAD inhibition protocol[85].”
Limitations of Stem Cell Therapy for Parkinson’s Disease
Li, Z., Peng, S., Jia, O. Y., & Liu, R. (2026) · Cells · doi:10.3390/cells15090839
“When these cells differentiated into mid-brain dopaminergic neurons, cells from the patient produced twice the amount of α -syn as neurons from the unaffected relative [75].”
Comini, G., Patton, T., Drummond, N. J., Barbato, M. I., Treacy, O., Ryan, A. E., Kunath, T., & Dowd, E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.09.731056
“Human NAS2 iPSCs (Devine et al., 2011) were maintained on laminin-521-coated plates in iPSC brew medium.”
Self-citationKarpilovsky, N. C., Goiran, T., Senkevich, K. A., Deyab, G., Twells, N. M., Cha, E. N., MacDougall, E. J., Wang, Z., Sirois, J., MacLeod, G. D. A. H., et al. (2026) · medRxiv · doi:10.64898/2026.09.09.26362627
Boumpoureka, I., Heider, J., Delcambre, S., Borgmann, F. B. K., Poret, A., Boussaad, I., Wilbertz, J. H., Sommer, P., Mittelbronn, M. G. A., Grünewald, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.09.750343
Okano, A., Miya, F., Kosaki, K., Nakahara, J., & Ito, D. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154675
Zebrafish models provide insight into the biological classification of Parkinson's disease
Mohamed, W., & Outeiro, T. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27702-3.00032-7
Metadata
- Authors
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Roslin Institute (GB)
- University of Tsukuba (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Devine, Michael J.
- Kunath, Tilo
- ORCID
- Venue
- Nature Communications
- Published
- 2011-08-23
- Volume
- 2
- Issue
- 1
- Pages
- 440-440
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3265381
- OpenAlex
- W1985010554
- Cited by
- 486
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- ASEP (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- University of Dundee
- Wellcome Trust (089698)
- Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
- Brain Research Trust
- University of Sheffield
- Medical Research Council (MC_G1000735)
- Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
- MeSH terms
- Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.